Lung Cancer (NSCLC)

Evidence-based overview of berberine in non-small-cell lung cancer, including p53-independent growth arrest, cancer-stem-cell effects, and ferroptosis-linked findings

Non-small-cell lung cancer is a strong berberine setting because it combines metabolic vulnerability, frequent treatment resistance, and common mutation burdens in pathways berberine appears to affect.

Why berberine is relevant here

NSCLC often involves difficult biology around:

EGFR and related signalling
p53 disruption
acquired resistance
cancer stem-cell persistence
high oxidative-stress adaptation

Berberine's mechanisms overlap with each of these.

Main mechanisms in NSCLC

p53-independent growth arrest

One of the most useful findings is that berberine does not appear to rely on intact p53 to slow NSCLC growth.

In models including p53-deficient cells, berberine still produced significant growth arrest.

That matters because p53 disruption is common in lung cancer.

Cancer stem-cell suppression

Berberine has also been shown to reduce cancer stem-like features in NSCLC models.

That is relevant because stem-like populations are linked to recurrence and persistent treatment resistance.

Apoptosis signalling

Reported work also supports apoptosis through the miR-19a / tissue factor / MAPK axis.

In NSCLC, berberine has also been studied alongside ferroptosis-inducing strategies.

These models suggest downregulation of SLC7A11, GPX4, and Nrf2, with lower glutathione and greater ferroptotic pressure.

Practical interpretation

NSCLC is one of the clearer examples of berberine as a resistance-oriented metabolic adjunct under investigation.

The strongest points are:

activity even in p53-deficient settings
stem-cell suppression interest
overlap with ferroptosis biology
mechanistic relevance to EGFR-driven and oxidative-stress-buffered disease

The evidence remains preclinical, but it is coherent and clinically relevant enough to justify attention.

References